BMP3 Suppresses Osteoblast Differentiation of Bone Marrow Stromal Cells Via Interaction With Acvr2b.

Shoichiro Kokabu
Laura Gamer
Karen Cox
Jonathan W. Lowery Ph.D.
Marian University - Indianapolis, jlowery@marian.edu
Kunikazu Tsuji

See next page for additional authors

Follow this and additional works at: http://mushare.marian.edu/com_fp
Part of the Cells Commons, and the Genetics and Genomics Commons

Recommended Citation
Authors
Shoichiro Kokabu, Laura Gamer, Karen Cox, Jonathan W. Lowery Ph.D., Kunikazu Tsuji, Regina Raz, Aris Economides, Takenobu Katagiri, and Vicki Rosen

This article is available at MUSHare: http://mushare.marian.edu/com_fp/12
BMP3 Suppresses Osteoblast Differentiation of Bone Marrow Stromal Cells via Interaction with Acvr2b

Shoichiro Kokabu, Laura Gamer, Karen Cox, Jonathan Lowery, Kunikazu Tsuji, Regina Raz, Aris Economides, Takenobu Katagiri, and Vicki Rosen

Department of Developmental Biology (S.K., L.G., K.C., J.L., V.R.), Harvard School of Dental Medicine, Boston, Massachusetts 02115; Section of Orthopedic Surgery (K.T.), Tokyo Medical and Dental University, Tokyo 113-8510, Japan; Regeneron Pharmaceuticals (R.R., A.E.), Tarrytown, New York 10591; and Division of Pathophysiology (T.K.), Saitama Medical University, Saitama 359-8513, Japan

Enhancing bone morphogenetic protein (BMP) signaling increases bone formation in a variety of settings that target bone repair. However, the role of BMP in the maintenance of adult bone mass is not well understood. Targeted disruption of BMP3 in mice results in increased trabecular bone formation, whereas transgenic overexpression of BMP3 in skeletal cells leads to spontaneous fracture, consistent with BMP3 having a negative role in bone mass regulation. Here we investigate the importance of BMP3 as a mediator of BMP signaling in the adult skeleton. We find that osteoblasts (OBL) and osteocytes are the source of BMP3 in adult bone. Using in vitro cultures of primary bone marrow stromal cells, we show that overexpression of BMP3 suppresses OBL differentiation, whereas loss of BMP3 increases colony-forming unit fibroblasts and colony-forming unit OBL. The ability of BMP3 to affect OBL differentiation is due to its interaction with activin receptor type 2b (Acvr2b) because knockdown of endogenous Acvr2b in bone marrow stromal cells reduces the suppressive effect of BMP3 on OBL differentiation. These findings best fit a model in which BMP3, produced by mature bone cells, acts to reduce BMP signaling through Acvr2b in skeletal progenitor cells, limiting their differentiation to mature OBL. Our data further support the idea that endogenous BMPs have a physiological role in regulating adult bone mass. (Molecular Endocrinology 26: 87–94, 2012)
bodies or soluble receptor decoys found reducing the availability of TGF-β or activin leads to significant gains in bone formation, identifying these factors as negative regulators of adult bone mass (13–16). In contrast, enhanced BMP signaling appears to play a positive role, because reducing the levels of the BMP antagonists noggin or gremlin enhances bone formation in the adult skeleton (17, 18). BMP3, a receptor antagonist specific for the type II receptor activin receptor type 2b (Acvr2b), appears to serve a unique role in the adult skeleton. Adult mice lacking BMP3 have increased bone mass, whereas mice with increased BMP3 levels in bone show delayed endochondral ossification with spontaneous rib fractures (19, 20). However, the cellular targets of BMP3 and the molecular mechanisms used by BMP3 to affect bone formation remain to be completely elucidated. In the present study, we use a LacZ knock-in allele to the BMP3 locus (BMP3 LacZ knock-in) to identify osteoblasts (OBL) and osteocytes (OCY) as the bone cells responsible for BMP3 production in the adult skeleton. We show that BMP3 targets osteoprogenitor cells where it inhibits BMP signaling. We define the interaction of BMP3/Acvr2b as a key event in BMP-mediated OBL differentiation by demonstrating that knockdown of endogenous Acvr2b diminishes the suppressive effect of BMP3 on osteoprogenitor cells. In addition, we find that loss of BMP3 increases colony-forming unit fibroblasts (CFU-F) and colony-forming unit OBL (CFU-OB) in BSMC cultures. Taken together, these data confirm that BMP3, secreted by OBL and OCY, regulates trabecular bone formation by regulating the differentiation of BSMC, thus identifying BMP3 as a novel target for bone mass augmentation.

**Results**

**BMP3 is expressed by OBL and OCY**

Using VelociGene technology (21), a BMP3-null mouse was generated where the first exon (encoding the N-terminal part of the precursor region) was replaced in frame with the lacZ reporter gene (BMP3 LacZ knock-in) to identify osteoblasts (OBL) and osteocytes (OCY) as the bone cells responsible for BMP3 production in the adult skeleton. We show that BMP3 targets osteoprogenitor cells where it inhibits BMP signaling. We define the interaction of BMP3/Acvr2b as a key event in BMP-mediated OBL differentiation by demonstrating that knockdown of endogenous Acvr2b diminishes the suppressive effect of BMP3 on osteoprogenitor cells. In addition, we find that loss of BMP3 increases colony-forming unit fibroblasts (CFU-F) and colony-forming unit OBL (CFU-OB) in BSMC cultures. Taken together, these data confirm that BMP3, secreted by OBL and OCY, regulates trabecular bone formation by regulating the differentiation of BSMC, thus identifying BMP3 as a novel target for bone mass augmentation.

**FIG. 1.** OBL and OCY express BMP3. Tibia from BMP3 4-wk-old LacZ knock-in mice stained for β-galactosidase. Diaphyseal region is shown in the top panel. The boxed areas in the upper panel are shown as magnified images (×20) of cortical bone (CB) and trabecular bone (TB) in lower panels. Arrowheads and arrows indicate OBL and OCY, respectively. BM, Bone marrow; PO, periosteum.

**BMP3 inhibits Smad signaling and suppresses OBL differentiation**

We next wanted to determine the effects of BMP3 on skeletal progenitor cell differentiation in vitro. As a source for BMP3 protein, we transfected W20-17 cells with BMP3 expression vectors. W20-17 cells are an osteoprogenitor cell line that requires BMP signaling for OB differentiation (2). Conditioned medium from W20-17 cells transfected with control or BMP3 containing pcDEF3 expression vectors were analyzed by Western blot, and BMP3 expression was verified (Fig. 2A). We then examined the effects of overexpression of BMP3 in skeletal progenitor cells and found that it suppressed the osteogenic activity of BMP4 and BMP2 in all cells examined including W20-17 (Fig. 2, B and C); ST2, a mouse bone marrow stromal cell line (Fig. 2D); and primary BSMC (Fig. 2E). Furthermore, BMP3 also suppressed expression of osteocalcin, a marker of mature OBL in cells treated with osteogenic BMP (Fig. 2F). To determine whether the inhibitory effects of BMP3 target canonical BMP signaling, we analyzed phosphorylation of endoge-
nous Smad1/5/8 by Western blotting and activation of the IdWT4 BMP-responsive reporter in W20-17 cells. Although transfection of cells with BMP4 or BMP2 resulted in increased p-Smad1/5/8 levels and robustly activated IdWT4F-luc, coexpression of BMP3 reduced BMP4-induced phosphorylation of Smad1/5/8 (Fig. 3A) and also suppressed IdWT4F-luc reporter activity induced by coexpression of BMP4 (Fig. 3B) or BMP2 (Fig. 3C) in a dose-dependent manner. BMP3 appeared to directly suppress BMP signaling and not act by changing levels of BMP antagonists, because transcript levels for chordin, noggin, and gremlin were not altered in mouse BSMC treated with BMP3-conditioned media (data not shown).

Suppressive effects of BMP3 on OBL differentiation require Acvr2b

We previously reported that BMP3 interferes with BMP signaling by binding to the multifunctional type II BMP/activin receptor Acvr2b (22). Allendorph et al. (23) confirmed these data by showing that BMP3 receptor specificity for Acvr2b is controlled through the interaction of lysine 30 of BMP3 and glutamic acid 76 of Acvr2b. To investigate whether BMP3 suppresses OB differentiation via its specific interaction with Acvr2b, we examined the effects of BMP3 on cells in which endogenous Acvr2b had been knocked down using small interfering RNA (siRNA). As a first step, we confirmed that W20-17 cells express Acvr2b and found that Acvr2b is the most abundant type II BMP receptor in these cells (Fig. 4A). We next confirmed that transfection of W20-17 cells with siRNA specific for Acvr2b significantly reduced protein levels of endogenous Acvr2b in Western blots (60% knockdown) when compared with cells transfected or treated with an empty vector (Vec) or conditioned medium from empty vector-transfected cells in each group.

**FIG. 2.** BMP3 suppresses OBL differentiation induced by BMP in osteoprogenitor cells. A, Western blot of conditioned medium from W20-17 cells transfected with empty vector or BMP3 verifies BMP3 expression. B and C, W20-17 cells were transfected with empty vector or BMP3, and then ALP activity was stimulated by cotransfection with BMP2 or BMP4. BMP3 significantly reduced the BMP-induced ALP activity. D and E, ST2 cells and primary BSMC that had been transfected with BMP4 to stimulate ALP activity were treated with control (vector) or BMP3-conditioned medium from W20-17 cells. BMP3-conditioned medium reduced ALP activity in both cell types. F, W20-17 cells cotransfected with BMP3 and BMP4 expressed reduced levels of osteocalcin (OC) on d 3, as determined by quantitative real time PCR analysis. Data are shown as the mean ± SD (n = 3). *, P < 0.05; **, P < 0.01 in comparison with cells transfected or treated with an empty vector (Vec) or conditioned medium from empty vector-transfected cells in each group.

**FIG. 3.** BMP3 suppresses BMP-Smad signaling. A, W20-17 cells were cotransfected with empty vector or BMP3 along with BMP4. At 24 h after transfection, protein levels were determined by Western blot. The protein levels were quantified by using Image J software. Smad1 was used for protein normalization. BMP3 reduced the amount of phospho-(P)-Smad1/5/8 induced by BMP4. B and C, W20-17 cells were cotransfected with 0, 30, 60, or 90 ng BMP3 expression vector or 0, 30, 60, or 90 ng empty vector along with 45 ng IdWT4F-luc reporter and 15 ng phRL-SV40 internal control vector. Luciferase activity was then stimulated by transfection of 50 ng BMP4 expression vector (B) or 50 ng BMP2 expression vector (C). BMP3 was able to reduce the luciferase activity induced by both BMP4 and BMP2. Data are shown as the mean ± SD (n = 3). **, P < 0.01 in comparison with cells transfected with an empty vector and BMP4 or BMP2 in each group.
We then tested the ability of BMP3 to reduce BMP4-mediated IdWT4F-luc and alkaline phosphatase (ALP) activation in the Acvr2b knockdown cells. We found that BMP3 could no longer block BMP4 activation of the BMP luciferase reporter (Fig. 4C) or induction of ALP activity (Fig. 4D), consistent with the finding that BMP3 binds and acts specifically through Acvr2b (24, 25). To confirm our RNA interference (RNAi) studies, we used C2C12 cells, which have been reported to lack expression of Acvr2b and should prevent them from being targeted by BMP3 (23–25). Although we detected low levels of Acvr2b by quantitative PCR in our C2C12 cells (Fig. 4E), we found that BMP3 was unable to block ALP activity induced by BMP treatment (Fig. 4F). Taken together, these findings confirm that the suppressive effect of BMP3 on OBL differentiation requires Acvr2b.

**Absence of BMP3 increases CFU-F and CFU-OB from BMSC**

If endogenous BMP3 functions to regulate OBL differentiation from BMSC, then mice lacking BMP3 should have an enhanced basal level of OBL differentiation. To investigate this idea, we harvested BMSC from BMP3-null mice and wild-type littermates and tested these cells in standard CFU-F and CFU-OB assays. BMSC that reside in a BMP3-null environment show an increase in CFU-F colony number and colony size (Fig. 5, A and B). In addition, the number of ALP-positive colonies produced by BMSC from mice lacking BMP3 and their spontaneous differentiation into OBL lineage cells was significantly increased in the absence of exogenous osteogenic signals when compared with wild-type controls (Fig. 5, C and D). These data confirm that loss of BMP3 results in increased differentiation of early OBL precursors into mature OBL and further suggest a negative role for BMP3 in adult bone.

**Discussion**

In the present study, we examined the cellular targets and molecular mechanisms that underlie the inhibition of BMP-induced OBL differentiation by BMP3, leading to the high-bone-mass phenotype in the BMP3 knockout.
mice (19, 22, 23). We demonstrate that this inhibition is due to the interaction of BMP3 with the type II receptor, Acvr2b, present on skeletal progenitor cells. BMP3/Acvr2b binding occurs upstream of type I receptor function, an idea supported by the pathological endochondral ossification that occurs when type II receptor control is bypassed in fibrodysplasia ossificans progressiva (7, 8).

Our results show that in adult bone, BMP3 is produced by OBL and OCY. Removing BMP3 from the bone environment increased CFU-F colony number and colony size as well as the spontaneous differentiation of osteoprogenitors into bone-forming cells. These data suggest a model of BMP3 activity in the skeleton whereby BMP3 produced by mature bone cells acts to limit the differentiation of Acvr2b-positive osteoprogenitors residing in the bone marrow microenvironment (Fig. 6). Osteoprogenitors not only express Acvr2b but also have other type II receptors (Acvr2a, BMPR-II, and transforming growth factor beta type II receptor) that are used by BMP/TGF-β/activin ligands to regulate signal transduction in bone. This fact is highlighted by recent data showing that systemic administration of a TGF-β-neutralizing antibody to adult mice increased bone mass and bone density, suggesting that TGF-β signaling via transforming growth factor beta type II receptor on BMSC limits osteogenesis (13, 14, 26). In addition, systemic administration of AR2AFc (soluble activin type II A receptor) and AR2BFc (soluble activin type II B receptor) type II activin receptor decoys also increases bone mass in vivo, and administration of AR2AFc to BMP3-null mice further increases bone mineral density (15, 16, 27). Taken as a whole, these data point to the potential therapeutic benefits of increasing bone formation through modulating the interactions between type II receptors and BMP/TGF-β/activins and suggest that BMP3 and its specific interaction with Acvr2b may be a novel means to enhance osteogenesis.

**Materials and Methods**

**Animals**

BMP3−/− mice were previously generated and described elsewhere (19). BMP3 LacZ knock-in mice were generated at Regeneron Pharmaceuticals using Velocigene technology (28). The region of the BMP3 gene containing exon 1 was deleted and replaced with a transmembrane-lacZ/neo...
more than 50 cells were counted. For CFU-OB assays, forma-
cu-f were stained with methylene green, and colonies with 
were washed twice with PBS and fixed with cold ethanol, and 
10 and 28 d of culture. At the end of each experiment, cultures 
well). The formation of CFU-F and CFU-OB was evaluated after 

Plasmids
Plasmids encoding wild-type human BMP3 (accession num-
bearer NM_001201.2) were obtained by a standard RT-PCR tech-
nique using PrimeSTAR HS DNA polymerase (TaKaRa, Ohtsu, 
Japan) and cloned into a pcDEF3 expression vector (30). The 
human BMP2, BMP4, mouse constitutively active Smad1, and 
IdWT4F-luc reporter plasmids have been previously described 
(10, 31).

Cell culture and transfection
W20-17 cells were cultured and maintained as described pre-
viously (2). ST2 cells were purchased from the RIKEN Cell Bank 
(Tsukuba, Japan). ST2 cells were cultured and maintained in 
α-MEM supplemented with 10% fetal bovine serum. Primary 
BSCM were collected from femurs and Tibias of 6-wk-old wild-
type C57BL/6J mice or BMP3−/− mice. After epiphyses were 
removed, bone was flushed with 15 ml α-MEM using a 20-ml syringe fitted with a 23-gauge needle. Flushed bone marrow 
cells were cultured with α-MEM containing 15% fetal bovine serum for 4 d (32). Cells were transfected with plasmids using 
Lipofectamine 2000 (Invitrogen) (33). Conditioned media were 
collected from W20-17 cells 3 d after transfection with empty 
vector, BMP3, or BMP4 for each assay.

ALP and luciferase assays
ALP activity was measured as a marker of OBL differentia-
tion on d 2. Cells treated with an acetone/ethanol (50:50) mixture 
were incubated with a substrate solution composed of 0.1 M diethanolamine, 1 mM MgCl2, and 1 mg/ml p-nitrophenylphos-
phate. The reaction was terminated by adding 3 M NaOH, and 
absorbance values were measured at 405 nm (34, 35). Lu-
ciferase assays were performed using IdWT4F-luc, phRL-SV40 
(Promega, Madison, WI) with the Dual-Glo Luciferase Assay 
System (Promega) (36).

CFU-F and CFU-OB assay
Primary BSCM were plated in triplicate cultures (six-well plates) at two different densities (1.0 × 10^6 or 1.5 × 10^6 cells per well). The formation of CFU-F and CFU-OB was evaluated after 10 and 28 d of culture. At the end of each experiment, cultures 
were washed twice with PBS and fixed with cold ethanol, and 
CFU-F were stained with methylene green, and colonies with 
more than 50 cells were counted. For CFU-OB assays, forma-
tion of OBL progenitors and OBL was detected using ALP and 
alizarin red staining (37). For ALP staining, cells were incubated for 20 min with a mixture of 0.1 mg/ml naphthol AS-MX phospho-
phate (Sigma-Aldrich Chemicals, St. Louis, MO), 0.5% N,N-
dimethylformamide, 2 mM MgCl2, and 0.6 mg/ml fast red TR salt 
(Sigma-Aldrich) in 0.1 M Tris-HCl (pH 8.5) at room tempera-
ture. The density of ALP staining was quantified by using Image 
J (National Institutes of Health, Bethesda, MD) software. For 
alizarin red staining, the cells were immersed in a 40 mM alizarin 
(Sigma-Aldrich) solution (pH 4.2) for 20 min at room tempera-
ture with gentle agitation. The solution then was removed, and the 
mineralized matrices were washed with water.

Trichloroacetic acid (TCA) precipitation
To concentrate the BMP3 protein, TCA precipitation was performed on medium collected from W20-17 cells that were 
transfected with BMP3 expression vectors. A 25-ml volume of 
medium was collected, and 10 times the sample volume of 10% 
TCA was added and incubated on ice for 1.5 h. This was fol-
lowed by centrifugation at 4000 × g for 15 min at 4 C. The TCA 
was aspirated, 400 µl acetic acid was added, and the sample was 
vortexed vigorously and then centrifuged at 12000 × g for 10 
min at 4 C. The acetic acid was aspirated, and the sample was 
dried at room temperature for 5 min. Finally, lysis buffer was added, and the sample incubated at 37 C for 5 min before Western blot 
analysis (38).

Western blot analysis
The following antibodies were used for Western blot analy-
sis: anti-BMP3 polyclonal antibody, anti-Acrt2b polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA), anti-
phosphorylated Smad1/5/8 polyclonal antibody, anti-Smad1 polyclonal antibody (Cell Signaling, Beverly, MA), and anti-β-
actin mouse monoclonal antibody (Sigma-Aldrich). The target 
proteins were detected using a horseradish peroxidase-conju-
gated antimouse, antirabbit IgG antibody (Cell Signaling), or 
anti-goat IgG antibody (Santa Cruz). Protein levels were quan-
tified using Image J software.

Reverse transcription and quantitative 
PCR analysis
Total RNA was isolated from W20-17 cells using Trizol 
(Invitrogen, Carlsbad, CA) and then reverse transcribed into 
cDNA using Superscript III (Invitrogen). The cDNA was ampli-
fied by PCR using specific primers for murine osteocalcin 
(primer sequences: forward, gaggcctgcctgtga; reverse, 
tgtagctgtcgcttagga), BMPRII (primer sequences: forward, 
gaggcctgcctgtga; reverse, gaggcctgcctgtcgcttagga), Acvr2a (primer 
sequences: forward, gaggcctgcctgtcgcttagga; reverse, 
gaggcctgcctgtcgcttagga), and β-actin. Quantitative real-time PCR was performed using the Roche (Indianapolis, IN) Light Cycler 480 Real-time PCR system with probe-based 
detection (Universal Probe Library; Roche). Values were normal-
ized to β-actin using the 2-ΔΔCt method (39).

RNAi transfection
RNAi Stealth oligonucleotides were designed against murine Acvr2b (no. MSS201683; Invitrogen), and a scrambled RNAi 
was used as a negative control (Invitrogen). Cells were tran-
scribed using bacterial homologous recombination. All studies 
performed were approved by the Institutional Animal Care and 
Use Committee at Harvard Medical School (Boston, MA).

X-gal staining
Tibias were collected from 4-wk-old BMP3 LacZ knock-in 
mice and littermate controls. Tissues were fixed for 24 h at 4 C 
in 4% paraformaldehyde/PBS (pH 8), decalcified at 4 C in 0.5 M 
EDTA (pH 7.4) for 10–14 d, equilibrated in 15% sucrose for 
1 h, 30% sucrose overnight at 4 C, and cryo-embedded. For 
X-gal staining, 20-µm sections were postfixed in 4% parafor-
maldehyde, washed three times for 15 min in 2 mM MgCl2, 
0.01% sodium deoxycholate, 0.02% Nonidet P-40 in PBS, 
stained overnight in 0.1% X-gal, 5 mM potassium ferrocyanide, 
5 mM potassium ferricyanide in PBS (pH 8) overnight at 37 C, and 
counterstained with eosin/floxin (29).
fected with siRNA using N-TER Nanoparticle siRNA Transfection System according to the manufacturer’s instructions (Sigma-Aldrich).

**Statistical analysis**

Comparisons were made using an unpaired Student’s t test; the results are shown as means ± SD. Statistical significance is indicated as P < 0.05 or P < 0.01.

**Acknowledgments**

Address all correspondence and requests for reprints to: Laura Gamer, Harvard School of Dental Medicine, Developmental Biology, 188 Longwood Avenue, Boston, Massachusetts 02115. E-mail: laura_gamer@hsdm.harvard.edu.

This work was supported by Grant AR50174 from National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH) (to V.R.).

Disclosure Summary: S.K., L.G., K.C., J.L., K.T., T.K., and V.R. have nothing to declare. R.R. was previously employed by Regeneron Pharmaceuticals and had equity interests in Regeneron Pharmaceuticals. A.E. is employed by Regeneron Pharmaceuticals and has equity interests in Regeneron Pharmaceuticals.

**References**


